Improving Medication Management for Inpatients with a Secondary Diagnosis of Parkinson Disease.
Journal
The American journal of nursing
ISSN: 1538-7488
Titre abrégé: Am J Nurs
Pays: United States
ID NLM: 0372646
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
25
4
2024
Statut:
ppublish
Résumé
Patients who have Parkinson disease require individualized medication regimens to optimize care. A review of the medication management of patients admitted to a tertiary care hospital with a secondary diagnosis of Parkinson disease found significant departures from the patients' home regimen. Medication regimens are often altered by health care teams unfamiliar with Parkinson disease-specific care in order to conform to standard hospital medication orders and administration times, potentially resulting in increased patient falls, delirium, and mortality.A nurse-led multidisciplinary team consisting of pharmacy, nursing, informatics, neurology, and quality personnel implemented a quality improvement (QI) project between July 2020 and July 2022 to identify patients with Parkinson disease, including those with a secondary diagnosis and those undergoing deep brain stimulation, and customize medication management in order to reduce length of stay, mortality, falls, falls with harm, and 30-day readmissions. The QI project team also evaluated patient satisfaction with medication management.Among patients with a secondary diagnosis of Parkinson disease, the proportion who had medication histories conducted by a pharmacy staff member increased from a baseline of 53% to more than 75% per month. For all patients with Parkinson disease, those whose medication history was taken by a pharmacy staff member had orders matching their home regimen 89% of the time, whereas those who did not had orders matching the home regimen only 40% of the time. Among patients with a secondary diagnosis of Parkinson disease, the length-of-stay index decreased from a baseline of 1 to 0.94 and observed-to-expected mortality decreased from 1.03 to 0.78. The proportion of patients experiencing a fall decreased from an average of 5% to 4.08% per quarter, while the proportion of patients experiencing a fall with harm decreased from an average of 1% to 0.75% per quarter. The rate of 30-day readmissions decreased from 10.81% to 4.53% per quarter. Patient satisfaction scores were 1.95 points higher for patients who had medication histories taken by pharmacy than for those who did not (5 versus 3.05).
Identifiants
pubmed: 38661703
doi: 10.1097/01.NAJ.0001016384.47848.89
pii: 00000446-202405000-00025
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-57Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Katz S, et al. Parkinson's disease is associated with increased complications, readmission rates, and costs of care after total hip arthroplasty: a matched-cohort analysis. The Journal of Hip Surgery 2020;4(3):149–54.
Cerri S, Blandini F. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease. Expert Opin Pharmacother 2020;21(18):2279–91.
Allen NE, et al. Recurrent falls in Parkinson's disease: a systematic review. Parkinsons Dis 2013;2013:906274.
GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):939–53.
Maserejian N, et al. Estimation of the 2020 global population of Parkinson's disease (PD) [abstract 198]. Mov Disord 2020;35(Suppl 1).
Azmi H, et al. Development of a Joint Commission disease-specific care certification program for Parkinson disease in an acute care hospital. J Neurosci Nurs 2019;51(6):313–9.
Chou KL, et al. Quality improvement in neurology: 2020 Parkinson disease quality measurement set update. Neurology 2021;97(5):239–45.
Hommel A, et al. The association of comorbidity with Parkinson's disease-related hospitalizations. Parkinsonism Relat Disord 2022;104:123–8.
Okunoye O, et al. Rate of hospitalizations and underlying reasons among people with Parkinson's disease: population-based cohort study in UK primary care. J Parkinsons Dis 2022;12(1):411–20.
Kwei K, Frucht S. Acute presentation of nonmotor symptoms in Parkinson's disease. Int Rev Neurobiol 2017;134:973–86.
Lertxundi U, et al. Medication errors in Parkinson's disease in patients in the Basque Country. Parkinsonism Relat Disord 2017;36:57–62.
Seppi K, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord 2019;34(2):180–98.
Weintraub D, et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 2016;73(5):535–41.
The Joint Commission. Disease-specific care certification review process guide. Oakbrook Terrace, IL; 2024 Jan. https://www.jointcommission.org/-/media/tjc/documents/accred-and-cert/survey-process-and-survey-activity-guide/2024/disease-specific-care-organization-rpg.pdf.
Fleenor LM, et al. Validation and evaluation of a prior-to-admission medication list discrepancy risk-scoring tool. J Am Coll Clin Pharm 2023;6(12):1321–29.